2-Ethoxy-3-methylpyrazine
Common Name: |
2-Ethoxy-3-methylpyrazine |
IUPAC Name: |
2-ethoxy-3-methylpyrazine |
Molecular Formula: |
C7H10N2O |
SMILES: |
CCOC1=NC=CN=C1C |
Inchi: |
1S/C7H10N2O/c1-3-10-7-6(2)8-4-5-9-7/h4-5H,3H2,1-2H3 |
Inchi Key: |
MMKWCKGYULOKET-UHFFFAOYSA-N |
Cas No: |
32737-14-7 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
2 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
138.17 |
Mass (g/mol) |
138.079 |
Molar Refractivity |
38.30 |
Net Charge |
|
HBD |
|
HBA |
3 |
Rt Bonds |
2 |
Rings |
1 |
TPSA |
35.01 |
Hetero Atoms |
3 |
Heavy Atoms |
10 |
Aromatic Heavy Atoms |
6 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
180.00 to 181.00 |
Vapor Pressure (mmHg@25.00 °C) |
1.167 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.43 |
LogP |
1.184 |
iLOGP |
1.99 |
XLOGP3 |
1.82 |
WLOGP |
1.18 |
MLOGP |
0.01 |
ESOL Log S |
-2.16 |
ESOL Solubility (mg/ml) |
0.966 |
ESOL Solubility (mol/l) |
0.007 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-2.18 |
Ali Solubility (mg/ml) |
0.92 |
Ali Solubility (mol/l) |
0.01 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-2.54 |
Silicos-IT Solubility (mg/ml) |
0.4 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.85 |
Bioavailability Score |
0.55 |
Caco2 |
0 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.759 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
1.606 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |